JSPR vs. AURA, SLDB, CRBU, DCGO, ADPT, OCGN, TCRX, ITOS, MGTX, and SOPH
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Aura Biosciences (AURA), Solid Biosciences (SLDB), Caribou Biosciences (CRBU), DocGo (DCGO), Adaptive Biotechnologies (ADPT), Ocugen (OCGN), TScan Therapeutics (TCRX), iTeos Therapeutics (ITOS), MeiraGTx (MGTX), and SOPHiA GENETICS (SOPH). These companies are all part of the "medical" sector.
Aura Biosciences (NASDAQ:AURA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
Aura Biosciences has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 5.9% of Aura Biosciences shares are owned by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Jasper Therapeutics' return on equity of -42.20% beat Aura Biosciences' return on equity.
Jasper Therapeutics received 12 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 82.76% of users gave Jasper Therapeutics an outperform vote while only 46.15% of users gave Aura Biosciences an outperform vote.
Aura Biosciences is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Jasper Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for Jasper Therapeutics and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.91 beat Jasper Therapeutics' score of 0.50 indicating that Jasper Therapeutics is being referred to more favorably in the news media.
Aura Biosciences presently has a consensus price target of $21.00, suggesting a potential upside of 192.89%. Jasper Therapeutics has a consensus price target of $64.17, suggesting a potential upside of 214.54%. Given Aura Biosciences' higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Aura Biosciences.
Summary
Jasper Therapeutics beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
